Inhibition of METTL3 expression in CRC cells reduces the MDSCs accumulation, maintains the activation and proliferation of CD4+ T cells and CD8+ T cells, and inhibits the progression of CRC (Chen et al. 2022). The gene discussed is METTL3; the disease is colorectal carcinoma.